{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:03:43Z","timestamp":1790643823395,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Hereditary cancer awareness has entered a new phase. For decades, awareness has focused on recognizing familial risk, identifying pathogenic germline variants, and helping families access counselling, surveillance and prevention. Yet in 2026, the main challenge is no longer only whether a variant can be detected, but how inherited risk can be interpreted, communicated and translated into action in the biological context of each tissue and tumor. The recent publication landscape of\n                    <jats:italic>Hereditas<\/jats:italic>\n                    illustrates this shift: cancer genetics is now inseparable from RNA regulation, epigenetics, metabolism, immune context, cellular plasticity, therapy resistance, computational modelling and precision intervention. This Editorial argues that hereditary cancer awareness must move beyond the variant without moving away from the familial risk. One step in this direction could be to use multi-omics as a bridge between genetic risk and precision prevention.\n                  <\/jats:p>","DOI":"10.1186\/s41065-026-00738-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:48:52Z","timestamp":1790642932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the variant: hereditary cancer awareness in the multi-omics era"],"prefix":"10.1186","volume":"163","author":[{"given":"Julhash U","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Massoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"1","key":"738_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s41065-025-00556-8","volume":"162","author":"JU Kazi","year":"2025","unstructured":"Kazi JU, Massoumi R. Why Hereditas leads hereditary cancer awareness now more than ever. Hereditas. 2025;162(1):180. https:\/\/doi.org\/10.1186\/s41065-025-00556-8.","journal-title":"Hereditas"},{"issue":"2","key":"738_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","volume":"22","author":"H LaDuca","year":"2020","unstructured":"LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, Yadav S, Hu C, Na J, Goldgar DE, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407\u201315. https:\/\/doi.org\/10.1038\/s41436-019-0633-8.","journal-title":"Genet Med"},{"issue":"1","key":"738_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13053-022-00240-2","volume":"20","author":"RJ Scott","year":"2022","unstructured":"Scott RJ. Modifier genes and Lynch syndrome: some considerations. Hered Cancer Clin Pract. 2022;20(1):35. https:\/\/doi.org\/10.1186\/s13053-022-00240-2.","journal-title":"Hered Cancer Clin Pract"},{"key":"738_CR4","doi-asserted-by":"crossref","unstructured":"Sauer M, Lucas MC, Prokosch V, Kessler T, Risch T, Laner A, Henkel J, Benet-Pages A, Hallermayr A, Steinke-Lange V et al. Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics. Int J Cancer. 2025. https:\/\/doi.org\/10.1002\/ijc.70274.","DOI":"10.1002\/ijc.70274"},{"issue":"1","key":"738_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41065-025-00431-6","volume":"162","author":"C Li","year":"2025","unstructured":"Li C, Hu J, Li M, Mao Y, Mao Y. Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma. Hereditas. 2025;162(1):61. https:\/\/doi.org\/10.1186\/s41065-025-00431-6.","journal-title":"Hereditas"},{"key":"738_CR6","doi-asserted-by":"crossref","unstructured":"Yin Y, Huang Y, Lin L, Cui M, Zhong L. The role of miR-557 in modulating cervical cancer malignancy by targeting TAOK1. Hereditas. 2026;163(1):87. https:\/\/10.1186\/s41065-026-00695-6.","DOI":"10.1186\/s41065-026-00695-6"},{"key":"738_CR7","doi-asserted-by":"crossref","unstructured":"Lan D, Sun X, Yao L, Cao B. miR-1229-3p promotes epithelial-mesenchymal transition and metastasis of cervical cancer cells by targeting FBXL5. Hereditas. 2026;163(1):72. https:\/\/10.1186\/s41065-026-00679-6.","DOI":"10.1186\/s41065-026-00679-6"},{"key":"738_CR8","doi-asserted-by":"crossref","unstructured":"Pang Z, Huang B, Cui Y, Ma S, Zheng B, Zhang X, Liu Y. miR-4513 promotes the proliferation and metastasis of non-small cell lung cancer cells by targeting VIPR1. Hereditas. 2026;163(1):83. https:\/\/10.1186\/s41065-026-00688-5.","DOI":"10.1186\/s41065-026-00688-5"},{"key":"738_CR9","doi-asserted-by":"crossref","unstructured":"Wang Y, Shen L, Cao R, Xu H, Guo Z, Chen Y, Wang D. miR-3913-3p promoted the progression of lung adenocarcinoma by regulating STX3 expression. Hereditas. 2026;163(1):48. https:\/\/10.1186\/s41065-026-00654-1.","DOI":"10.1186\/s41065-026-00654-1"},{"key":"738_CR10","doi-asserted-by":"crossref","unstructured":"Su J, Gu J, Lu Z. MIR9-3HG\/let-7c-5p\/THBS1 axis promotes hepatocellular carcinoma progression. Hereditas. 2026;163(1):90. https:\/\/10.1186\/s41065-026-00694-7.","DOI":"10.1186\/s41065-026-00694-7"},{"key":"738_CR11","doi-asserted-by":"crossref","unstructured":"Zhao Y, Shen H, Sun Y, Song J, GuangSun C, Li J, Wang H, Song Y. Extracellular matrix-growth factor signalling drives the oncogenic mir-125b-2\/UCK2 axis in hepatocellular carcinoma. Hereditas. 2026;163(1):59. https:\/\/10.1186\/s41065-026-00673-y.","DOI":"10.1186\/s41065-026-00673-y"},{"key":"738_CR12","doi-asserted-by":"crossref","unstructured":"Song X, Kong D, Zi Y, Wang X, Ni J. Folate-driven changes in snoRNA function: a novel epigenetic-ribosomal axis in hepatocellular carcinoma. Hereditas. 2026;163(1):56. https:\/\/10.1186\/s41065-026-00666-x.","DOI":"10.1186\/s41065-026-00666-x"},{"key":"738_CR13","doi-asserted-by":"crossref","unstructured":"Mu T, Zhang S, Zhong Y, Zhou Z, Xie L, Zhou Y, Zhang W, Zhai L. Identification and external validation of a prognostic signature based on myeloid-derived suppressor cell-related lncRNAs for hepatocellular carcinoma. Hereditas. 2026;163(1):54 . https:\/\/10.1186\/s41065-026-00664-z.","DOI":"10.1186\/s41065-026-00664-z"},{"key":"738_CR14","doi-asserted-by":"crossref","unstructured":"Al-Dayan N. A comprehensive analysis of the Cullin family reveals that CUL5 and CUL7 promote colorectal cancer progression and serve as prognostic markers. Hereditas. 2026;163(1):71. https:\/\/10.1186\/s41065-026-00677-8.","DOI":"10.1186\/s41065-026-00677-8"},{"key":"738_CR15","doi-asserted-by":"crossref","unstructured":"Hua B, Wang W, Huang H, Chang X, Ye T. Development and validation of a succinylation-related prognostic model for esophageal squamous cell carcinoma based on multi-omics bioinformatics analysis. Hereditas. 2026;163(1):44. https:\/\/10.1186\/s41065-026-00653-2.","DOI":"10.1186\/s41065-026-00653-2"},{"key":"738_CR16","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu N, Dong X, Li Y, Geng J, Li Y. A prognostic model for gastric cancer based on histamine-associated prognostic genes. Hereditas. 2026;163(1):53. https:\/\/10.1186\/s41065-026-00659-w.","DOI":"10.1186\/s41065-026-00659-w"},{"key":"738_CR17","doi-asserted-by":"crossref","unstructured":"Que Y, Song Y, Huang D, Wu X, Pan Y. miR-4652-3p suppresses glutamine metabolism induced by the inflammatory microenvironment in non-small cell lung cancer by regulating MYC\/SLC1A5. Hereditas. 2026;163(1):40. https:\/\/10.1186\/s41065-026-00649-y.","DOI":"10.1186\/s41065-026-00649-y"},{"key":"738_CR18","doi-asserted-by":"crossref","unstructured":"Chen N, Wang T, Li Y, Zhang R, Wei X, Wang Z. TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response. Hereditas. 2026;163(1):84. https:\/\/10.1186\/s41065-026-00690-x.","DOI":"10.1186\/s41065-026-00690-x"},{"key":"738_CR19","doi-asserted-by":"crossref","unstructured":"Liu X, Shi A, Dai B, Chang Y, Yun F, Guan H, Sha R, Jia Y. Cancer-associated fibroblasts and immune escape-related genes serve as biological markers for the prognosis of colorectal cancer. Hereditas. 2026;163(1):60. https:\/\/10.1186\/s41065-026-00676-9.","DOI":"10.1186\/s41065-026-00676-9"},{"key":"738_CR20","doi-asserted-by":"crossref","unstructured":"Olvera-Valencia M, Grijalva-Perez A, Millan-Catalan O, Albino-Sanchez ME, Chairez-Ramirez MH, Mendez-Martinez R, Lopez-Urrutia E, Perez-Plasencia C, Garcia-Carranca A. Cellular plasticity and heterogeneity underlying therapy resistance in 3D cervical cancer models. Hereditas. 2026;163(1):64. https:\/\/10.1186\/s41065-026-00668-9.","DOI":"10.1186\/s41065-026-00668-9"},{"key":"738_CR21","doi-asserted-by":"crossref","unstructured":"Jia CC, Li ZY, Jia WH, Jiang CT. Integrated bioinformatics analysis and experimental validation reveal Pevonedistat as a promising therapeutic agent modulating the CRL4-DTL-p21\/p53 axis in nasopharyngeal carcinoma. Hereditas. 2026;163(1):50. https:\/\/10.1186\/s41065-026-00661-2.","DOI":"10.1186\/s41065-026-00661-2"},{"key":"738_CR22","doi-asserted-by":"crossref","unstructured":"Wu P, Chen L, Yang J, Liang Z, Yin X, Zhou S, Deng Z, Yang Y. STEAP2-associated modulation of PI3K\/AKT\/mTOR signaling contributes to ginkgetin-induced apoptosis in bladder cancer cells. Hereditas. 2026;163(1):76. https:\/\/10.1186\/s41065-026-00686-7.","DOI":"10.1186\/s41065-026-00686-7"},{"key":"738_CR23","doi-asserted-by":"crossref","unstructured":"Farah H, Kadhim-Abosaoda M, Mohaisen-Mousa H, Jyothi SR, Priyadarshini-Nayak P, Janney JB, Singh G, Singh-Chauhan A, Kumar-Mishra M. Exploring 14-3-3zeta: insights into its role in cancer mechanisms and future therapeutic applications. Hereditas. 2026;163(1):47. https:\/\/10.1186\/s41065-026-00658-x.","DOI":"10.1186\/s41065-026-00658-x"},{"key":"738_CR24","doi-asserted-by":"crossref","unstructured":"Marei HE. Enhancer-based gene therapy: a new path for precision medicine. Hereditas. 2026;163(1):46. https:\/\/10.1186\/s41065-026-00655-0.","DOI":"10.1186\/s41065-026-00655-0"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00738-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:48:57Z","timestamp":1790642937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00738-y","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.U.K.: Conceptualization, Writing \u2013 original draft, review & editing. R.M.: Conceptualization, Writing \u2013 original draft, review & editing.","order":2,"name":"Ethics","label":"Authors contributions","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}